Kevin McHenry

Kevin McHenry has a strong background in the medical field, with experience in various roles as a Medical Science Liaison. Kevin is currently working at GRAIL as a Sr. Medical Science Liaison. Prior to this, they held the position of Medical Science Liaison, Director of NET and Radiosensitive Tumors at Novartis Oncology from January 2021 to March 2023. Before Novartis, they worked as a Medical Science Liaison at Advanced Accelerator Applications from August 2020 to January 2021.

Kevin has also gained valuable experience at prominent companies such as Genentech, where they served as a Medical Science Liaison II from September 2017 to August 2020. At Genentech, they played a crucial role in bio-oncology MSL for BGGO (Breast, GI, and Gyn Oncology) and served as a disease lead for non-HCC GI MSL. Kevin actively participated in key clinical trial launches and successfully established relationships with previously inaccessible institutions.

Prior to their time at Genentech, Kevin worked as an Oncology Medical Science Liaison at AstraZeneca from September 2015 to September 2017. During their tenure, they were a part of the Pan Tumor Team, where they were involved in launching the company's first checkpoint inhibitor, IMFINZI. Kevin also served as the Study and Insight Lead for SCCHN (Squamous Cell Carcinoma of the Head and Neck).

Before their roles in the medical industry, Kevin worked as a Research Investigator at MetaStat from January 2014 to February 2015. Kevin also served as a Research Scientist at Astellas Pharma from July 2011 to August 2013, where they were involved in primary biology lead responsibilities and initiated siRNA screen in breast cancer cell panel.

Kevin began their career as a Presidental Postdoctoral Fellow at Novartis Institutes for BioMedical Research from July 2008 to June 2011. During this time, they focused on studying mechanisms of cancer cell resistance to apoptosis and synthetic lethality. Kevin also published peer-reviewed articles from their academic collaboration.

Kevin holds a PhD in Cancer Biology from the University of Illinois at Chicago, where they started as a Graduate Student in August 2000 and successfully discovered a small molecule inhibitor of cell migration and adhesion.

Kevin McHenry earned a Bachelor of Science degree in Chemistry from The University of Dallas between 1993 and 1997. Subsequently, they pursued a Ph.D. in Biochemistry at the University of Illinois Chicago from 2000 to 2006.